Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Eterna Therapeutics ( (ERNA) ).
On February 6, 2026, Ernexa Therapeutics Inc. entered into agreements for a best-efforts public offering of 19,000,000 common shares with accompanying warrants and 2,000,000 pre-funded warrants with accompanying warrants, priced at $0.50 and $0.49 respectively. The warrants, which began trading on Nasdaq under the symbol ERNAW on February 6, 2026, are immediately exercisable at $0.68 per share and will expire five years after issuance or 180 days after initial Phase 1 ERNA-101 cohort data are publicly released, whichever comes first.
The offering, conducted with Brookline Capital Markets as exclusive placement agent and declared effective by the SEC on February 5, 2026, closed on February 10, 2026, delivering approximately $10.5 million in gross proceeds to Ernexa before fees and expenses. The company plans to use the net proceeds to advance its development programs, fund working capital and general corporate purposes, while agreeing to 90-day restrictions on additional equity issuances and variable-rate transactions, as well as lock-ups for officers and directors, signaling near-term balance sheet reinforcement and disciplined capital-raising constraints for existing shareholders.
More about Eterna Therapeutics
Ernexa Therapeutics Inc. is a Cambridge, Mass.-based biotechnology company developing innovative allogeneic cell therapies for advanced cancers and autoimmune diseases. Its platform engineers induced pluripotent stem cells into synthetic induced mesenchymal stem cells, with lead candidates ERNA-101 for ovarian cancer and ERNA-201 for inflammatory and autoimmune indications.
The company’s off-the-shelf iMSC therapies aim to provide scalable immunomodulatory treatments without patient-specific cell harvesting. By focusing on immune activation against tumors and regulation of inflammatory pathways, Ernexa is positioning itself within the competitive cell and gene therapy market targeting high unmet medical needs.
Average Trading Volume: 227,215
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.42M
For an in-depth examination of ERNA stock, go to TipRanks’ Overview page.